# Giredestrant

Type: Product

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/giredestrant
Canonical HTML page: https://gethealthbrief.com/entity/giredestrant

## Timeline

- **2026-03-09**: Trial Failure Announced — Roche confirms the oral SERD candidate failed to meet primary endpoints; shares dip immediately.
- **2025-11-15**: Phase II Data Review — Earlier data had suggested potential efficacy, leading to high investor expectations for the Phase III results.
- **2024-06-10**: Combination Trials Launch — Roche expanded the program to include combination therapies with CDK4/6 inhibitors.

## Recent coverage (1 stories)

### Roche Shares Retreat After Oral Breast Cancer Drug Fails Pivotal Trial
2026-03-09 13:49:01 · Sentiment: Negative · Impact: 7/10 · Sources: 4

Roche's stock fell on March 9, 2026, following the failure of its oral breast cancer candidate in a key clinical trial. This setback complicates the Swiss pharmaceutical giant's efforts to modernize its oncology portfolio and compete in the lucrative oral SERD market.
Full story: https://gethealthbrief.com/story/roche-shares-dip-oral-breast-cancer-drug-failure

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.